Pricing Log in Create free account

Cytokinetics, Incorporated (CYTK) vs Spyre Therapeutics, Inc. (SYRE)

Cytokinetics, Incorporated and Spyre Therapeutics, Inc. are both Biotechnology companies. Spyre Therapeutics, Inc. is the larger, with a market value of $9.2B against $7.7B — 1.2× the size. Cytokinetics, Incorporated grew revenue faster over the last twelve months: 29.9% against −81.8%. Spyre Therapeutics, Inc. has the higher net margin (0.00% vs −686.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Spyre Therapeutics, Inc. leads on 9 and Cytokinetics, Incorporated on 7.

Valuation

Metric CYTK SYRE Biotechnology median
P/E n/m n/m 10.26
P/S 64.40 8,159.98 9.18
P/B n/m 9.50 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 65.85 7,142.99 8.98
Earnings yield (10.93%) (3.16%) (34.89%)
Free cash flow yield (8.07%) (2.89%) (24.52%)

Profitability

Metric CYTK SYRE Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin (625.15%) 0.00% 0.00%
Net margin (686.63%) 0.00% 0.00%
Free cash flow margin (519.53%) 0.00% 0.00%
Return on equity 184.71% (41.15%) (50.12%)
Return on assets (47.70%) (30.89%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CYTK SYRE Biotechnology median
Revenue growth (TTM) 29.90% (81.84%) 6.26%
EPS growth (last fiscal year) (24.33%) 55.24% 29.88%
Revenue growth, 5-year CAGR 9.54% (28.15%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CYTK SYRE Biotechnology median
Debt to equity (0.54) 0.00 0.00
Current ratio 3.36 27.40 4.89
Net debt to EBITDA (0.46) 3.61 1.01

Dividend

Metric CYTK SYRE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CYTK SYRE Biotechnology median
Market cap 7.72b 9.17b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack